CTX110
CRSP-ONC-001
Phase 2 mab terminated
Quick answer
CTX110 for B-cell Malignancy is a Phase 2 program (mab) at CRISPR Therapeutics AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CRISPR Therapeutics AG
- Indication
- B-cell Malignancy
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated